Literature DB >> 1246237

[Neuraminidase induced hemolytic anemia. Experimental and clinical observations (author's transl)].

A Poschmann, K Fischer, A Grundmann, A Vongjirad.   

Abstract

Recently, increasing attention has been focussed on the in vivo action of neuraminidase as possible pathogenetical factor of hemolytic anemia and even hemolytic-uremic syndrome. Neuraminidase action in red cell membranes results in the release of neuraminic acid, and thereby the uncovering of previously hidden receptors, socalled cryptantigens. With special reference to the phythemagglutinin Anti-TAh from the peanut (Arachis hypogae) and the agglutinin Anti-AHP from the albumin gland of the small Helix pomatia we describe some new methods for the detection of these cryptantigens. In addition to the screebubg genagglutination test with Anti-TAh we developed an "Anti-T-consumption test" for quantitative detection of neuraminidase action on red cells. With the purified reagents we developed an indirect fluorescnet antibody method on blood smears for the detection of cryptantigens on single cells. By animal experiments we could show that not only the membranes of red cells but the intima of renal capillaries as well are damaged by neuraminidase. With these new methods we observed 14 patients suffering from hemolytic anemia due to bacterial or viral neuraminidase. Some of these patients developed a hemolytic-uremic syndrome. We believe that the positive reaction with Anti-T Ah should lead to prophylactic heparinization to prevent dissiminated intravascular coagulation. Neuraminidase is the first identified toxin which directly acts on the membranes of red cells and the intima of renal capillaries as well, and thereby in some patients may induce hemolytic-uremic syndrome. Possibly, these results may stimulate the development of further testsystems for the detection of still unknown toxins which are not tested with our reagents, but may equally be involved in the damage of cell membranes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1246237

Source DB:  PubMed          Journal:  Monatsschr Kinderheilkd


  5 in total

1.  Red blood cell T-activation and hemolysis in surgical intensive care patients with severe infections.

Authors:  G Lenz; U Goes; D Baron; U Sugg; W Heller
Journal:  Blut       Date:  1987-02

Review 2.  [Clinical aspects of the hemolytic-uremic syndrome].

Authors:  M Brandis
Journal:  Klin Wochenschr       Date:  1979-10-01

3.  Endotheliotropic (hemolytic) nephroangiopathy and its various manifestation forms (thrombotic microangiopathy, primary malignant nephrosclerosis, hemolytic-uremic syndrome).

Authors:  W Thoenes; H D John
Journal:  Klin Wochenschr       Date:  1980-02-15

4.  Monoclonal antibodies for the detection of desialylation of erythrocyte membranes during haemolytic disease and haemolytic uraemic syndrome caused by the in vivo action of microbial neuraminidase.

Authors:  R C Seitz; A Poschmann; H H Hellwege
Journal:  Glycoconj J       Date:  1997-09       Impact factor: 2.916

5.  Cholestatic jaundice in the haemolytic-uraemic syndrome: a case report.

Authors:  G Jeffrey; C C Kibbler; R Baillod; K Farrington; M Y Morgan
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.